Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18433308 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CYP2A6TP53TDP1PIM1 | |
| SCHEMBL18936100 | 0.79 | HSP90AA1 (0.31) | CYP2A6 | |
| SCHEMBL18433135 | 0.78 | TP53 (0.39) | ALDH1A1CYP2A6TP53TDP1PIM1 | |
| SCHEMBL3483474 | 0.72 | CA2 (0.59) | — | |
| SCHEMBL18936057 | 0.71 | CYP2A6 (0.53) | CYP2A6TP53TDP1MAPT | |
| SCHEMBL2090846 | 0.71 | HSP90AA1 (0.52) | ALDH1A1CYP2A6MAPT | |
| SCHEMBL18935983 | 0.71 | DYRK1A (0.52) | MAPT | |
| SCHEMBL2092117 | 0.71 | NOS1 (0.31) | — | |
| SCHEMBL2092450 | 0.71 | TUBB4A (0.39) | ALDH1A1CYP2A6TDP1MAPTPKM | |
| SCHEMBL2092742 | 0.71 | CYP2A6 (0.38) | ALDH1A1CYP2A6TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3178323-B1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2021-06-23 | — | — | EP | disclosed |
| US-10251396-B2 | Amide compound and use of same for noxious arthropod control | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-9854803-B2 | Noxious arthropod control agent containing amide compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-10-19 | — | — | US | disclosed |
| US-20170215424-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-3178323-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
| EP-3178322-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | Sumitomo Chemical Company Limited (JP) | 2017-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170295789-A1 | AMIDE COMPOUND AND USE OF SAME FOR NOXIOUS ARTHROPOD CONTROL | OPRM1, TRPA1, L3MBTL3 | ALDH1A1 1868/4885CYP2A6 1673/4885TP53 4807/4885 |
| US-20170215424-A1 | NOXIOUS ARTHROPOD CONTROL AGENT CONTAINING AMIDE COMPOUND | TRPA1, OPRM1, OPRL1 | ALDH1A1 2079/4885CYP2A6 1424/4885TP53 4832/4885 |
| US-10251396-B2 | Amide compound and use of same for noxious arthropod control | OPRM1, TRPA1, L3MBTL3 | ALDH1A1 1868/4885CYP2A6 1673/4885TP53 4807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.